Programme

xi

Programme Thursday, 12 May 10:45 Welcome Dominik Berthold, CH Alberto Costa, IT/CH Representative of the Town of Lugano 11:00 1. Epidemiology in Europe [Invited]

Cristina Bosetti, IT

11:15 Localised invasive bladder cancer Chair: Alex Bex, NL 41. Neo-adjuvant chemotherapy [Invited] 2. Surgery [Invited] 3. Radiotherapy [Invited]

Joachim Bellmunt, ES George Thalmann, CH Nicholas James, UK

12:30

4. Palliative chemotherapy: First-line, second-line, platinum-unfit [Invited]

Maria De Santis, AT

13:00

Lunch and Poster session

14:00 Oral abstract presentations Chair: Ian Tannock, CA 25. Ex-vivo ultrasound control of resection margins during partial nephrectomy 26. Reasonability of lymph dissection in localized types of renal cell carcinoma 27. Quality of life in metastatic renal cell carcinoma patients with ECOG PS >2 receiving targeted therapy 28. Choosing the extent of the lymph node dissection in surgical treatment of the bladder cancer with regional metastasis 14:45 5. Mechanisms of action in modern RCC treatment [Invited] (Lecture sponsored by Novartis Oncology) 15:15

Yannick Cerantola, CH Nodir Rahimov, UZ Ilya Tsimafeyeu, RU Otabek Ergashev, UZ Christian Rothermundt, CH

Coffee break

15:45 Kidney cancer Chair: George Thalmann, CH 6. First and further lines in mRCC [Invited] 7. Adjuvant and neo-adjuvant treatment [Invited] Non-clear cell histology [Invited] 8. Surgery, including nephron-sparing surgery [Invited] 18:15 9. Keynote lecture: New developments in the systemic treatment of advanced prostate cancer [Invited] (this lecture will be webcast as part of the e-grandround programme www.e-eso.net) 19:00 Welcome cocktail

Brian I. Rini, US Alex Bex, NL Joachim Bellmunt, ES Hendrik Van Poppel, BE Ian Tannock, CA

xii

Programme / Critical Reviews in Oncology/Hematology 78 S1 (2011) xi−xiv

Friday, 13 May 8:30

10:30

Prostate cancer: From biology to life expectancy Chair: Chris Parker, UK 10. Biology [Invited]

Zoran Culig, AT

Screening and active surveillance [Invited] 11. Predicting life expectancy [Invited]

Freddie C. Hamdy, UK Catherine Terret, FR

Coffee break

11:00 Prostate cancer: All the truth about local treatment options T1−T2 Chair: Freddie C. Hamdy, UK Radiotherapy [Invited] 12. Surgery [Invited] 13. Brachytherapy [Invited]

Anders Widmark, SE Vincenzo Ficarra, IT Jan J. Battermann, NL

14. High-intensity focused ultrasound and cryotherapy [Invited]

Fran¸cois J. Murat, FR

12:20 Oral abstract presentations Chair: Dominik Berthold, CH 29. On the role of magnetic resonance imaging with Endorectal Coil (ER-MRI) in changing the stage (and treatment approach) in patients with early prostate cancer undergoing primary radiation

Mario Romano, IT

30. Weight change analysis in advanced castration resistant prostate cancer Diletta Bianchini, UK (CRPC) patients treated with Abiraterone Acetate (AA) single agent and in combination with steroids 31. Evaluating the antitumour activity of docetaxel following treatment Janusz Mezynski, UK with abiraterone acetate and steroids: Evidence for cross-resistance 32. Current status of prostate cancer in Lagos, Nigeria 13:00

Olugbenga Adetayo, NG

Lunch and Poster session

14:00 Controversy: Locally advanced prostate cancer Moderator: Bertrand Tombal, BE 15. Pro surgery [Invited] 16. Pro radiation [Invited] Discussion and conclusion [Invited]

Axel Heidenreich, DE Chris Parker, UK Bertrand Tombal, BE

15:00

17. Locally advanced prostate cancer: Multimodality treatment and new drugs combined with radiotherapy [Invited]

St´ephane Supiot, FR

15:30

Coffee break

16:00 Prostate cancer: Locally advanced disease and patient advocacy Chair: Dominik Berthold, CH 18. Europa Uomo: The patients’ voice [Invited] Adjuvant versus salvage radiation [Invited]

Vincent Griesser, CH Michel Bolla, FR

Integrating systemic therapy into high-risk disease [Invited]

Karim Fizazi, FR

17:00 Prostate cancer: Management of pelvic nodes Chair: Axel Heidenreich, DE 19. Surgical perspective [Invited] Radiation perspective [Invited]

Hendrik Van Poppel, BE Thomas Wiegel, DE

Programme / Critical Reviews in Oncology/Hematology 78 S1 (2011) xi−xiv

Saturday, 14 May 9:00 20. Prostate cancer drug development [Invited] 10:00

21. SIOG guidelines for the management of prostate cancer in senior adults [Invited] (Lecture sponsored by Sanofi-Aventis)

10:30

Coffee break

11:00

22. Side-effects of anti-androgen therapy [Invited]

Johann S. de Bono, UK Catherine Terret, FR

Bertrand Tombal, BE

11:30 Bone targeted agents [Invited]

Noel Clarke, UK

12:00 Testicular cancer Chair: Noel Clarke, UK 23. Options in stage I testicular cancer [Invited] Treatment of advanced testicular cancer [Invited]

Alan Horwich, UK Karim Fizazi, FR

24. Role of surgery in the management of testis cancer [Invited] 13:30 Closing remarks Dominik Berthold, CH 13:40 Distribution of CME certificates and departures

Axel Heidenreich, DE

xiii

xiv

Programme / Critical Reviews in Oncology/Hematology 78 S1 (2011) xi−xiv

Poster Session 33. Pure red cell dysplasia in a patient with metastatic cancer prostate, Raafat Abdel Malek, EG 34. Role of immunehistochemical markers in definition of hormone sensation prostate cancer, Elena Kolesnikova, UZ 35. Intermittent hormonal therapy in the treatment of prostate cancer, Nodir Rahimov, UZ 36. Dural metastases from prostatic adenocarcinoma: Case report and review of literature, Ahmed Salem, JO 37. Multiple successive surgery and chemotherapy helped to dramatically prolong life in patient with bladder cancer, Elena Shakhnovich, RU 38. Cytoreductive nephrectomy in advanced or metastasis renal cell carcinoma: In the era of targeted strategies, Chrysovalantis Toutziaris, GR 39. Supraclavicular lymphadenopathy as the initial clinical symptom of a rare histological type of renal cancer, Chrysovalantis Toutziaris, GR 40. Atypical initial clinical presentation of a prostate cancer with normal PSA, Chrysovalantis Toutziaris, GR